Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively.

Journal: CNS drugs

Volume: 35

Issue: 7

Year of Publication: 2022

Affiliated Institutions:  Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK. Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK. d.s.baldwin@soton.ac.uk.

Abstract summary 

Monoamine oxidase inhibitors (MAOIs) were among the first licensed pharmacological treatments for patients with depression but over time have fallen out of mainstream clinical use. This has led to a loss of clinician training opportunities and reduced availability of MAOIs for prescribing. This article provides a concise and practical overview of how to use MAOIs safely and effectively in psychiatric practice. We consider the history of MAOIs, why they are not used more frequently, their mechanisms of action, availability, indications and efficacy, general tolerability, withdrawal symptoms, and safety considerations (including hypertensive reactions and serotonin syndrome). Practical advice is given in terms of dietary restrictions, interactions with other medications (both prescribed and non-prescribed), and how prescribers can stop and switch MAOIs, both within the drug class and outside of it. We also provide advice on choice of MAOI and treatment sequencing. Lastly, we consider emerging directions and potential additional indications.

Authors & Co-authors:  Chamberlain Samuel R SR Baldwin David S DS

Study Outcome 

Source Link: Visit source

Statistics
Citations :  Loomer HP, Saunders JC, Kline NS. A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Psychiatr Res Rep. 1957;8:129–41.
Authors :  2
Identifiers
Doi : 10.1007/s40263-021-00832-x
SSN : 1179-1934
Study Population
Male,Female
Mesh Terms
Depressive Disorder, Treatment-Resistant
Other Terms
Study Design
Cross Sectional Study
Study Approach
Country of Study
Publication Country
New Zealand